These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 12690409)
41. Insulin signaling as a therapeutic mechanism of lithium in bipolar disorder. Campbell IH; Campbell H; Smith DJ Transl Psychiatry; 2022 Aug; 12(1):350. PubMed ID: 36038539 [TBL] [Abstract][Full Text] [Related]
42. Modulation of cellular and synaptic variability in the lamprey spinal cord. Parker D; Bevan S J Neurophysiol; 2007 Jan; 97(1):44-56. PubMed ID: 17021027 [TBL] [Abstract][Full Text] [Related]
43. Treatment of bipolar disorder: new perspectives. Alda M; Hajek T; Calkin C; O'Donovan C Ann Med; 2009; 41(3):186-96. PubMed ID: 18821183 [TBL] [Abstract][Full Text] [Related]
44. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. McQuillin A; Rizig M; Gurling HM Pharmacogenet Genomics; 2007 Aug; 17(8):605-17. PubMed ID: 17622937 [TBL] [Abstract][Full Text] [Related]
47. Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Bauer M; Alda M; Priller J; Young LT; Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S250-4. PubMed ID: 14677087 [TBL] [Abstract][Full Text] [Related]
48. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Gould TD; Manji HK Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567 [TBL] [Abstract][Full Text] [Related]
53. Akt/GSK3 signaling in the action of psychotropic drugs. Beaulieu JM; Gainetdinov RR; Caron MG Annu Rev Pharmacol Toxicol; 2009; 49():327-47. PubMed ID: 18928402 [TBL] [Abstract][Full Text] [Related]
54. [Predictors of prophylactic response to lithium]. Rohayem J; Baylé JF; Richa S Encephale; 2008 Sep; 34(4):394-9. PubMed ID: 18922242 [TBL] [Abstract][Full Text] [Related]
55. The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Ghasemi M; Dehpour AR Trends Pharmacol Sci; 2011 Jul; 32(7):420-34. PubMed ID: 21492946 [TBL] [Abstract][Full Text] [Related]
56. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Chen G; Masana MI; Manji HK Bipolar Disord; 2000 Sep; 2(3 Pt 2):217-36. PubMed ID: 11249800 [TBL] [Abstract][Full Text] [Related]
57. Neuropeptide y in euthymic lithium-treated women with bipolar disorder. El Khoury A; Mathé AA Neuropsychobiology; 2004; 50(3):239-43. PubMed ID: 15365223 [TBL] [Abstract][Full Text] [Related]
58. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Bachmann RF; Schloesser RJ; Gould TD; Manji HK Mol Neurobiol; 2005 Oct; 32(2):173-202. PubMed ID: 16215281 [TBL] [Abstract][Full Text] [Related]
59. Interrelations between lithium therapy, auto-immune thyroiditis and TSH. A case report. Mouaffak F; Gourevitch R; Baup N; Lôo H; Olié JP Pharmacopsychiatry; 2006 Mar; 39(2):77-8. PubMed ID: 16555169 [No Abstract] [Full Text] [Related]
60. Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer's Disease, Lithium, and Autophagy. Damri O; Shemesh N; Agam G Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375448 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]